Vaccine

A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe. The agent stimulates the body's immune system to recognize the agent as foreign, destroy it, and "remember" it, so that the immune system can more easily recognize and destroy any of these microorganisms that it later encounters.

What are Vaccines?

There are several diseases like Diphtheria, whooping cough (pertussis), measles, mumps, Yellow fever, small pox and German measles (rubella) that are unfamiliar to many these days.

Vaccine History

Vaccine Schedule

Vaccine Effectiveness

Vaccine Production

Vaccine Excipients

Vaccine Delivery

Vaccine Immunity

Hib Immunization

History of Vaccination

Latest Vaccine News and Research

Tear-gassing protesters during an infectious outbreak ‘a recipe for disaster’

In nationwide demonstrations sparked by the killing of George Floyd in police custody, protesters have been frequently pepper-sprayed or enveloped in clouds of tear gas.

5 Jun 2020

T cells can counteract dangerous phenomenon of mosquito-borne viruses

Every year, more than 68,000 people end up with a clinical case of Japanese encephalitis. One in four of these patients will die. The mosquito-borne virus, which is most common in Southeast Asia, also causes severe neurological damage and psychiatric disorders.

5 Jun 2020

A SARS-CoV-2 antibody magnetic immuno-detection test

A new report, released on the preprint server bioRxiv by researchers at the Fraunhofer Institute for Molecular Biology and Applied Ecology, describes the development of an innovative serologic test that could provide a fast, easy, and inexpensive method of detecting high titers of antibody in the serum of SARS-CoV-2 infected people.

4 Jun 2020

Designing a prototype spike protein vaccine for SARS-CoV-2

A recent study published on the preprint server bioRxiv in June 2020 reports the development of a prototype vaccine containing multiple antigenic sites, based on the spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is causing the current COVID-19 pandemic. If successful, this could lead to the development of an effective, non-allergenic vaccine that induces both humoral and cellular immunity.

4 Jun 2020

Comparing genomes to understand how mutations affect the COVID-19 pandemic

Now, a new study by researchers at the Massachusetts Institute of Technology and the Center for Computational Biology, Flatiron Institute and published online on the bioRxiv preprint server describes how the use of comparative genomics helps to identify protein-coding and non-coding functional genes.

4 Jun 2020

Alpaca-derived antiviral agent neutralizes SARS-CoV-2

Researchers at Karolinska University Hospital and the University of Cape Town have identified an antibody fragment that targets the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein and potently neutralizes the virus.

4 Jun 2020

HPV vaccines that work in the U.S. may not be effective in protecting other populations of women

A research team at Dartmouth's and Dartmouth-Hitchcock's Norris Cotton Cancer Center has found that the same vaccination programs that target human papillomavirus (hrHPV) strains in the United States may not be as effective in protecting other populations of women from the disease.

4 Jun 2020

New technology to monitor anti-drug antibodies in MS patients may have potential for COVID-19 testing

A new study led by Queen Mary University of London has demonstrated the effectiveness of using a novel light technology to monitor the presence of anti-drug antibodies in the treatment of multiple sclerosis, which can lead to drug resistance and treatment failure.

4 Jun 2020

Immune responsive nanoparticles for COVID-19 vaccine delivery

Analytik reports how the renowned Quadram Institute has invested in a ZetaView Nanoparticle Tracking Analyser to help them develop a new approach for vaccine delivery based on engineering the natural ability of resident gut bacteria to generate nanoparticle sized Outer Membrane Vesicles.

From Analytik Ltd 4 Jun 2020

World’s first study of potential antibody therapy to fight COVID-19 begins in humans

Eli Lilly and Company today announced patients have been dosed in the world’s first study of a potential antibody treatment designed to fight COVID-19.

4 Jun 2020

Distancing, masks and eye gear protects against spread of SARS-CoV-2 finds large study

In a comprehensive systemic analysis of different studies, researchers have found that physical distancing, use of face masks, and eye protection were the most effective ways to prevent the spread of SARS-CoV-2 infection from one person to another.

4 Jun 2020

Study says vitamin-magnesium combo may reduce severity of COVID-19 in seniors

The COVID-19 pandemic that began in late December 2019 has spread to over 188 countries and territories, causing over 6.5 million cases and 385,000 deaths. With no effective therapeutic COVID-19 drug or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in sight, researchers are exploring different strategies to limit its spread and mortality.

4 Jun 2020

Tumors cause disruption of the immune system throughout the body, study finds

Cancer treatment has advanced with the advent of immunotherapies that, in some cancers, can overcome tumors' ability to evade the immune system by suppressing local immune responses.

3 Jun 2020

Study sheds new light on how respiratory virus breaks into cells to cause infection

New research from University of Alberta microbiologists has shed new light on how the respiratory syncytial virus (RSV)--one of the most common viral infections--breaks into our cells to cause infection.

3 Jun 2020

Study shows Sofosbuvir alleviates COVID-19-related neurological symptoms

A group of researchers has studied the effects of an antiviral drug Sofosbuvir on human brain organoids infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

2 Jun 2020

A vectored vaccine candidate against SARS-CoV-2

The current pandemic of COVID-19 is caused by the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), a betacoronavirus similar to that which caused the SARS-CoV and MERS-CoV earlier. Scientists are pursuing therapeutic drugs and vaccines to counter the relentless spread of the virus, but so far, none has been established to be effective. However, several are in clinical trials in various parts of the world.

2 Jun 2020

Cats resistant to SARS-CoV-2 reinfection

Researchers at Colorado State University have made important discoveries about domestic cats infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could address concerns about human-to-animal transmission and the role domestic pets might play in spreading the virus.

2 Jun 2020